The Karmanos Cancer Institute has expanded the capabilities of its clinical trials app, aiming to make it easier for patients, caregivers, and physicians to identify and explore active cancer studies.
The Karmanos Cancer Institute has introduced a significantly updated version of its KCI Clinical Trials App, reflecting a growing emphasis on improving access to clinical research through digital tools. Available for both Apple and Android devices, the updated platform is designed to help patients, caregivers, and healthcare professionals more easily discover actively recruiting cancer clinical trials across the Karmanos Cancer Network. As clinical research becomes an increasingly important part of cancer care, simplifying access to relevant studies can help patients better understand the treatment options available to them.
The updated application offers a range of practical improvements focused on usability and efficiency. Users can now search for trials using cancer type, study identifiers, investigators, treatment methods, drugs, devices, or keywords, while enhanced filtering helps narrow results more effectively. Expanded trial listings also provide additional details, including eligibility requirements, study objectives, treatment information, participating locations, and principal investigators, allowing users to evaluate opportunities without navigating multiple sources.
Beyond improving search capabilities, the app is intended to support communication between patients, physicians, and the institute. Patients can request appointments directly from individual trial listings, while healthcare providers can use the platform to refer patients for evaluation. The application also includes direct contact options for Karmanos specialists, enhanced drug information sourced from the National Cancer Institute Drug Dictionary, mapping tools for study locations, and the ability to save or share trial information through email or text. Offline functionality ensures the app remains usable even in areas with limited internet connectivity.
The institute currently lists more than 160 active clinical trial protocols led by 33 principal investigators across 13 locations, covering more than 35 cancer types. While these studies are also available through the national ClinicalTrials.gov database, the dedicated Karmanos platform provides a more focused resource for individuals specifically seeking opportunities within its regional network. By consolidating this information into a single application, the institute aims to reduce barriers that can sometimes make clinical research difficult to navigate.
Digital health tools are increasingly reshaping how patients engage with complex medical decisions, and clinical trial participation is no exception. By making research opportunities easier to find and understand, the Karmanos Cancer Institute’s updated app highlights how technology can support more informed conversations between patients and care teams while expanding awareness of emerging treatment options.
